Publications by authors named "S Tsuyoshi Ohnishi"

Introduction: The pathophysiology of burn wound conversion is not fully understood. Animal models are needed to elucidate the underlying mechanisms and develop treatments. Here, we established a new reproducible mouse model that simulates this process, thereby facilitating studies of burn wound conversion.

View Article and Find Full Text PDF

Aim: Atezolizumab/bevacizumab is a first-line therapy for unresectable hepatocellular carcinoma (HCC). Among several adverse events, grade ≥2 proteinuria is considered a significant adverse event that may cause bevacizumab interruption. Studies have shown that proteinuria might predict improved prognosis, although data are scarce and the association remains controversial, and the mechanisms and predictive factors remain unclear.

View Article and Find Full Text PDF

Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) comprises simple steatosis (SS), which has a low risk of mortality, and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to liver cirrhosis and hepatocellular carcinoma. Because differentiation between MASH and SS is the most important issue in the diagnosis of MASLD, the establishment of noninvasive diagnostic methods is urgently needed. In this study, we evaluated the potential of [I]IIMU, a thymidine phosphorylase (TYMP) targeted SPECT imaging probe, for differential diagnosis of MASLD in a preclinical animal model.

View Article and Find Full Text PDF

Background: Conditioned medium from amnion-derived mesenchymal stem cells (AMSCs) enhances wound healing, a process that is further improved under hypoxic culture conditions. Diabetic foot ulcers are difficult to treat and are frequently complicated by a high rate of bacterial infections, mainly Staphylococcus aureus, which can lead to limb amputation and death. Here, we topically applied conditioned medium from AMSCs cultured under hypoxic conditions to S.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness and safety of nivolumab and ipilimumab (NIVO+IPI) in elderly patients over 75 years with advanced renal cell carcinoma (RCC).
  • It involved 59 patients and compared treatment outcomes, such as response rates and survival, between those younger and older than 75.
  • Findings indicated no major differences in treatment effectiveness or severe side effects, but older patients showed better overall survival compared to younger ones.
View Article and Find Full Text PDF